+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

D

Actively Recruiting

Researchers are studying the effects of durvalumab, an immunotherapy drug, on various types of advanced or metastatic solid tumors in patients who have previously stopped checkpoint therapy due to immune-related side effects. They are also evaluating whether prednisone, a steroid, can help reduce these side effects when given with durvalumab. Additionally, the study allows patients from completed Canadian Cancer Trials Group CCTG trials to continue treatment with durvalumab, with or without tremelimumab. Participants receive durvalumab intravenously every four weeks, with prednisone given orally during the first two cycles to assess its impact on side effects. Some patients may also continue treatment with tremelimumab alongside durvalumab, depending on their previous trial enrollment. The study includes two substudies one focusing on patients who discontinued prior immunotherapy due to toxicity, and another allowing continued treatment for those already enrolled in completed CCTG trials. Throughout the study, participants undergo regular monitoring including laboratory tests and imaging to track disease status and side effects. Researchers record the number and severity of adverse events over two years, as well as treatment responses and the effectiveness of corticosteroids in preventing immune-related side effects. Patients are followed closely for treatment safety and efficacy, with a minimum life expectancy of 12 weeks required for participation.

Age: 18Years +All GendersPhase 2
11 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to explore the acceptability and feasibility of a co-payment model for recommended but unfunded vaccines in community pharmacies in Nova Scotia and Ontario. Many vaccines recommended by Canadas National Advisory Committee on Immunization are not publicly funded, which may limit vaccine uptake due to cost barriers. The study evaluates whether sharing vaccine costs between patients, private insurers, and the government can improve access and increase vaccination rates. The study involves a pilot of four different co-payment steps at up to eight community pharmacy sites, with each site randomly assigned to one step. These steps range from patients paying the full vaccine cost to full coverage by the study, with varying government and participant cost shares for vaccine and administration fees. Vaccines included are FluMist Quadrivalent, Shingrix, and Abrysvo or Arexvy RSV vaccines. Pharmacy providers will administer vaccines as part of routine care during the study. Participants will receive vaccines at reduced costs based on the assigned co-payment model and complete online surveys about their experiences and satisfaction. Pharmacy providers will also complete surveys about implementing the model. Researchers will track vaccine administration numbers before and during the pilot. The study will run for up to 30 months, with primary outcomes measured over 6 months, focusing on the models acceptability and feasibility among the public and providers.

Age: 2Years +All GendersPhase Not Applicable
2 locations
C

Actively Recruiting

This clinical trial investigates treatment options for men with unfavourable risk localized prostate cancer. Researchers are comparing a newer radiation method called Stereotactic Body Radiation Therapy SBRT, which uses higher doses over fewer sessions with special equipment, against the standard external beam radiation combined with a brachytherapy boost. The study aims to find out if SBRT is as effective as the standard approach in controlling prostate cancer progression. Participants will receive either the standard treatment involving external beam radiation to the pelvis and prostate plus a brachytherapy boost, combined with hormone therapy, or the experimental SBRT treatment delivering higher radiation doses in fewer sessions. Adjuvant androgen deprivation therapy ADT will be given according to risk level, lasting 6 months for intermediate risk and 24 months for high or very high risk. Treatments are assigned randomly to compare outcomes between groups. Throughout the study, participants will be monitored for cancer progression, side effects, and quality of life using questionnaires and medical assessments for up to 8.6 years. Researchers will track progression-free survival, PSA response, metastasis-free survival, and overall survival, as well as participant-reported tolerability and economic outcomes. Safety will be assessed continuously to understand how well participants tolerate the treatments over time.

Age: 18Years +MALEPhase 3
57 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness of Selective Laser Trabeculoplasty SLT at low energy compared to standard energy for treating glaucoma and ocular hypertension. The study also aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications than waiting to repeat standard energy SLT until its effects wear off. This is a Phase 3 randomized trial focusing on treatment optimization for these eye conditions. Participants initially receive SLT treatment at standard energy, where energy levels are adjusted to produce champagne bubbles as a sign of effectiveness. At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually with low energy or as needed with standard energy. The low energy SLT involves 100 treatment spots delivered at a lower energy level, adjusted as needed to maintain optimal response, while the standard energy SLT uses higher energy levels with similar adjustments. One arm of the initial low energy SLT was discontinued after interim analysis. Throughout the study, participants undergo regular eye pressure measurements and monitoring up to 48 months. Researchers measure outcomes such as survival without needing additional treatment at 12 and 48 months, average intraocular pressure IOP over time, and incidence of IOP spikes. Participants will attend scheduled visits for assessments and treatment as needed, with the total study duration lasting several years to evaluate long-term effects and safety.

Age: 18Years +All GendersPhase 3
29 locations
C

Actively Recruiting

Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.

Age: 18Years +All GendersPhase 3
299 locations
C

Actively Recruiting

Researchers are conducting a randomized, open-label phase 3 clinical trial to compare treatments for adults with advanced or metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitor therapy. The study focuses on two groups one receiving N-803 plus tislelizumab and docetaxel, and the other having previously failed immune checkpoint inhibitor therapy combined with docetaxel. The trial aims to evaluate the effectiveness and safety of these treatments compared to docetaxel alone. Participants are assigned to two cohorts and randomized in a 21 ratio to either the experimental treatment or control arm. Cohort A receives N-803, tislelizumab, and docetaxel during the first two 3-week cycles, followed by N-803 and tislelizumab until the study ends. Cohort B receives N-803, their prior failed checkpoint inhibitor, and docetaxel in the first two cycles, then N-803 and the prior checkpoint inhibitor thereafter. Control arms for both cohorts receive docetaxel monotherapy in repeated 3-week cycles. During the study, participants undergo treatment cycles every three weeks with scheduled administration of drugs via subcutaneous injection or intravenous infusion. Researchers will assess overall survival approximately 12 months after treatment begins. Participants must attend study visits and follow-ups as required. Safety and treatment effects will be monitored throughout the trial, which is expected to continue until January 2029.

Age: 18Years - 90YearsAll GendersPhase 3
49 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.

Age: 18Years +MALEPhase 3
395 locations

1-10 of 33

1